X
CRNX icon

Xponance’s Crinetics Pharmaceuticals CRNX Stock Holding History

Xponance’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$328K Buy
9,043
+1,848
+26% +$82.5K ﹤0.01% 1214
2025
Q4 		$335K Buy
7,195
+96
+1% +$4.27K ﹤0.01% 1125
2025
Q3 		$296K Buy
7,099
+98
+1% +$3.13K ﹤0.01% 1165
2025
Q2 		$201K Buy
7,001
+144
+2% +$4.45K ﹤0.01% 1330
2025
Q1 		$230K Buy
6,857
+573
+9% +$21.4K ﹤0.01% 1218
2024
Q4 		$321K Buy
6,284
+1,168
+23% +$65.3K ﹤0.01% 1105
2024
Q3 		$261K Buy
5,116
+186
+4% +$9.59K ﹤0.01% 1131
2024
Q2 		$221K Buy
+4,930
New +$228K ﹤0.01% 1150

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return